| Compounds | Topics | Title | Date |
|---|---|---|---|
| THC,CBN | pain in mice | delta9-Tetrahydrocannabinol and Cannabinol Activate Capsaicin-Sensitive Sensory Nerves via a CB1 and CB2 Cannabinoid Receptor-Independent Mechanism | June 2002 |
|
Action Pathway: extracellular calcium Here, we show that THC and cannabinol induce a CB1/CB2 cannabinoid receptor-independent release of calcitonin gene-related peptide from capsaicin-sensitive perivascular sensory nerves. Other psychotropic cannabinoids cannot mimic this action. | |||
| CBN | drug potentiator in humans via experiment (n=5) | Effects of delta9-tetrahydrocannabinol and cannabinol in man. | Jan 1975 |
|
Ingestion Method: 50 mg CBN, 25 mg delta9-THC, 12.5 mg delta9-THC + 25 mg CBN, and 25 mg delta9-THC + 50 mg CBN (orally). It appears that CBN increases the effect of delta9-THC on some aspects of physiological and psychological processes, but that these effects are small and cannot account for the greater potency which has been reported when plant material is used. | |||
| CBN | alzheimers in mice | Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival | Sept 2004 |
|
Ingestion Method: 5 mg/kg/day We found that this treatment significantly delays disease onset by more than two weeks while survival was not affected. Further research is necessary to determine whether non-psychotropic cannabinoids might be useful in ameliorating symptoms in ALS. | |||
| CBN,CBD,CBC,THC,CBN | anti-bacterial in vitro | anti-bacterial cannabinoids from Cannabis sativa: a structure-activity study. | August 2008 |
| All five major cannabinoids (cannabidiol (1b), cannabichromene (2), cannabigerol (3b), Delta (9)-tetrahydrocannabinol (4b), and cannabinol (5)) showed potent activity against a variety of methicillin-resistant Staphylococcus aureus (MRSA) strains of current clinical relevance | |||
| CBN,CBD,CBC,THC,CBN | anti-bacterial in vitro | anti-bacterial cannabinoids from Cannabis sativa: a structure-activity study. | August 2008 |
| All five major cannabinoids (cannabidiol (1b), cannabichromene (2), cannabigerol (3b), Delta (9)-tetrahydrocannabinol (4b), and cannabinol (5)) showed potent activity against a variety of methicillin-resistant Staphylococcus aureus (MRSA) strains of current clinical relevance | |||
| THC,CBN | alzheimers in model via model | Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimers Disease | May 2019 |
| Positive Pairwise combinations of THC and CBN lead to a synergistic neuroprotective interaction. Together, these results significantly extend the published data by showing that non-psychoactive cannabinoids are potential lead drug candidates for AD and other neurodegenerative diseases. | |||
| CBD,CBN,CBC | pain in rats | Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain | May 2019 |
| These results suggest that peripheral application of these non-psychoactive cannabinoids may provide analgesic relief for chronic muscle pain disorders such as temporomandibular disorders and fibromyalgia without central side effects. | |||